HYPE has declined 3.3% in 24 hours to $45.13 despite Hyperliquid platform recording historic $18.99 billion daily perpetuals ...

In July 2025, global markets have been navigating a complex landscape marked by new U.S. tariff announcements and mixed economic signals, with the Nasdaq Composite Index showing resilience amidst ...

In a recent market update, Goldman Sachs raised its year-end forecast for the S&P 500 (SPX) to 6,900 by year-end, up from a ...

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

IPO stocks like Circle and CoreWeave have highlighted a revived U.S. IPO market. But can the rebound in valuations last?

Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

The first half of 2025 was a roller-coaster ride for investors with the broader market surging to new highs at the beginning ...

Markets rise with Nasdaq topping 20,600, fueled by Nvidia's $4T milestone, U.S.-EU trade optimism and Fed's patient stance on rate changes. Treasuries rebound.

Impax Asset Management significantly reduced its position in Regeneron Pharmaceuticals by 53% in the first quarter, selling 1 ...